Intrexon (XON) Receiving Somewhat Favorable Media Coverage, Study Finds
Press coverage about Intrexon (NYSE:XON) has been trending somewhat positive on Wednesday, Accern reports. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Intrexon earned a news impact score of 0.12 on Accern’s scale. Accern also gave news stories about the biotechnology company an impact score of 45.9864626931307 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media headlines that may have impacted Accern Sentiment Analysis’s rankings:
- Intrexon (XON) Shares Cross Above 200 DMA (nasdaq.com)
- Intrexon (XON) Set to Announce Quarterly Earnings on Thursday (americanbankingnews.com)
- Intrexon to Present at the Jefferies 2018 Global Industrials Conference (finance.yahoo.com)
- Stock under Consideration— Intrexon Corporation (XON) (stockmarketstop.com)
- Global Synthetic Biology Industry – GenScript USA Inc., Intrexon Corporation, Thermo Fisher Scientific Inc., Synthetic … (theperfectinvestor.com)
Shares of Intrexon traded down $0.59, hitting $15.00, during trading on Wednesday, Marketbeat Ratings reports. The stock had a trading volume of 15,751 shares, compared to its average volume of 1,123,731. Intrexon has a 12 month low of $10.26 and a 12 month high of $21.66. The firm has a market capitalization of $1.90 billion, a P/E ratio of -16.48 and a beta of 1.08. The company has a debt-to-equity ratio of 0.01, a quick ratio of 1.93 and a current ratio of 2.16.
Several equities research analysts have weighed in on the company. Zacks Investment Research cut Intrexon from a “buy” rating to a “hold” rating in a report on Monday, July 16th. Bank of America cut Intrexon from a “neutral” rating to an “underperform” rating and set a $12.00 price objective for the company. in a report on Monday, July 16th. Finally, Stifel Nicolaus assumed coverage on Intrexon in a report on Tuesday, July 17th. They issued a “buy” rating and a $72.00 price objective for the company. Three equities research analysts have rated the stock with a sell rating, two have assigned a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Hold” and an average target price of $36.00.
In other news, CEO Randal J. Kirk bought 7,479,431 shares of the firm’s stock in a transaction dated Tuesday, July 3rd. The stock was purchased at an average price of $13.37 per share, with a total value of $99,999,992.47. The transaction was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Helen Sabzevari sold 8,402 shares of the stock in a transaction that occurred on Wednesday, July 18th. The stock was sold at an average price of $14.54, for a total value of $122,165.08. Following the completion of the transaction, the insider now directly owns 25,000 shares of the company’s stock, valued at approximately $363,500. The disclosure for this sale can be found here. 48.20% of the stock is currently owned by corporate insiders.
Intrexon Company Profile
Intrexon Corporation operates in the synthetic biology field in the United States. The company, through a suite of proprietary and complementary technologies, designs, builds, and regulates gene programs, which are DNA sequences that consist of key genetic components. Its technologies include UltraVector gene design and fabrication platform, and its associated library of modular DNA components; Cell Systems Informatics; RheoSwitch inducible gene switch; AttSite Recombinases; Protein Engineering; Laser-Enabled Analysis and Processing; and ActoBiotics and AdenoVerse technology platforms.
Featured Article: How Do I Invest in Dividend Stocks
Receive News & Ratings for Intrexon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Intrexon and related companies with MarketBeat.com's FREE daily email newsletter.